Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Marco Matucci-Cerinic"'
Autor:
Martina Orlandi, Laura Antonia Meliante, Arianna Damiani, Lorenzo Tofani, Cosimo Bruni, Serena Guiducci, Marco Matucci-Cerinic, Silvia Bellando-Randone, Sara Tomassetti
Publikováno v:
Pharmaceuticals, Vol 15, Iss 12, p 1584 (2022)
The role of Bronchoalveolar Lavage (BAL) in the evaluation of systemic sclerosis (SSc) interstitial lung disease (ILD) is still controversial. The aim of this systematic literature review was to investigate the use of BAL in SSc-ILD, and to focus on
Externí odkaz:
https://doaj.org/article/75b94888e5fa4e09acc853c9ea42b0bd
Autor:
Barbara Ruaro, Marco Confalonieri, Marco Matucci-Cerinic, Francesco Salton, Paola Confalonieri, Mario Santagiuliana, Gloria Maria Citton, Elisa Baratella, Cosimo Bruni
Publikováno v:
Pharmaceuticals, Vol 14, Iss 2, p 154 (2021)
Systemic sclerosis (SSc) patients are often affected by interstitial lung disease (ILD) and, although there have been recent treatment advances, it remains the leading cause of death among SSc, with a 10-year mortality up to 40%. African Americans an
Externí odkaz:
https://doaj.org/article/a501dc6162ca4d609f03f53d285a56e6
Autor:
Barbara Ruaro, Riccardo Pozzan, Paola Confalonieri, Stefano Tavano, Michael Hughes, Marco Matucci Cerinic, Elisa Baratella, Elisabetta Zanatta, Selene Lerda, Pietro Geri, Marco Confalonieri, Francesco Salton
Publikováno v:
Pharmaceuticals. 15:1033
Background: Idiopathic pulmonary fibrosis (IPF) is a rare and severe disease with a median survival of ∼3 years. Several risk factors have been identified, such as age, genetic predisposition, tobacco exposure, and gastro-oesophageal reflux disease
Autor:
Marco Matucci-Cerinic, Elisa Baratella, Francesco Salton, Marco Confalonieri, Barbara Ruaro, Gloria Maria Citton, Mario Santagiuliana, Cosimo Bruni, Paola Confalonieri
Publikováno v:
Pharmaceuticals
Pharmaceuticals, Vol 14, Iss 154, p 154 (2021)
Pharmaceuticals, Vol 14, Iss 154, p 154 (2021)
Systemic sclerosis (SSc) patients are often affected by interstitial lung disease (ILD) and, although there have been recent treatment advances, it remains the leading cause of death among SSc, with a 10-year mortality up to 40%. African Americans an